THALES
6.6.2022 14:02:12 CEST | Business Wire | Press release
As organisations continue their digital transformation journeys and move more of their workloads, networking, and security frameworks to the cloud, there is increasing pressure for businesses to rollout sufficiently robust security solutions to safeguard their networks. A long-standing collaboration between the two global cybersecurity leaders, Thales and Palo Alto Networks, will help support this widespread cloud migration, allowing organisations to implement Zero Trust security systems at scale. Through three technology integrations, businesses will gain access to Internal Resources within a robust, highly resilient security architecture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005079/en/
This news comes at a time where cloud transformation at enterprise-level is occurring at pace to support an increasingly hybrid working world. In line with this shift, it is critical that businesses secure distributed IT environments that no longer have a defined physical security perimeter. The combination of identity aware contextual access controls and multi-factor authentication systems will enable secure cloud transformation whilst supporting remote workforces, allowing employees to safely access any resource, from anywhere, and on any device.
Three key integrations
The integrations will minimise the threat of data breaches from identity compromise by implementing strong, adaptive authentication at the network edge and by ensuring automated remediation workflows in the event of an untrusted access event.
By integrating Thales’ SafeNet Trusted Access across Palo Alto Networks Prisma® Access, GlobalProtect, ML-Powered Next Generation Firewalls, and Cortex® XSOAR technologies, businesses will be able to deploy a Zero Trust model across a suite of solutions. Organisations will benefit from secure and adaptive multi-factor authentication, access management across edge solutions, network security policies, incident response and threat intelligence management.
“Thales has partnered with us to help support customers through their digital transformation journeys, and in collaboration we are well primed to provide a zero trust approach with authentication, SOC security and ZTNA solutions. With these integrations, businesses are able to seamlessly secure access to hybrid and cloud environments, detect suspicious account activity, automatically trigger alerts and enforce stronger access policies in real-time,” said Tana Rosenblatt, VP Technology Partnerships, at Palo Alto Networks.
“The business threat landscape is evolving rapidly, leading to an increase in the scale and complexity of risks being faced by many of our clients. As organisations move their network security to the cloud, it becomes more difficult to implement holistic security controls. We are excited to be able to work with Palo Alto Networks and offer organisations a clear path towards identity-aware Zero Trust security.
By applying and enforcing adaptive and multi-factor authentication at the network edge, and by responding to and stopping untrusted access events in real-time, Thales and Palo Alto Networks ensure organisations can make the move to the cloud successfully and securely,” concluded Francois Lasnier, VP Access Management Products at Thales.
For businesses looking to roll out Zero Trust frameworks within their networks, Thales and Palo Alto Networks security solutions are available to integrate now. To learn more about rolling out Zero Trust frameworks using Thales and Palo Alto Networks security solutions, join our RSA Conference roundtable session that discusses identity centric Zero Trust with Palo Alto Networks by reserving one of the limited seats here .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
